share_log

Cantor Fitzgerald Reiterates Overweight on Catalyst Pharmaceuticals, Maintains $25 Price Target

Cantor Fitzgerald Reiterates Overweight on Catalyst Pharmaceuticals, Maintains $25 Price Target

坎托·菲茨杰拉德重申增持Catalyst Pharmicals,维持25美元的目标股价
Benzinga ·  2023/06/21 09:59

Cantor Fitzgerald analyst Charles Duncan reiterates Catalyst Pharmaceuticals (NASDAQ:CPRX) with a Overweight and maintains $25 price target.

坎托·菲茨杰拉德分析师查尔斯·邓肯重申增持Catalyst Pharmicals(纳斯达克股票代码:CPRX),并维持25美元的目标股价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发